Price T Rowe Associates Inc Maxcyte, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 33,405 shares of MXCT stock, worth $118,587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,405
Previous 33,405
-0.0%
Holding current value
$118,587
Previous $131,000
0.76%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding MXCT
# of Institutions
124Shares Held
65.6MCall Options Held
1KPut Options Held
2K-
Cadian Capital Management, LP New York, NY8.19MShares$29.1 Million1.63% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$28.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.78MShares$20.5 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$17.9 Million7.62% of portfolio
-
Morgan Stanley New York, NY4.82MShares$17.1 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $361M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...